PMID- 30105512
OWN - NLM
STAT- MEDLINE
DCOM- 20181106
LR  - 20211204
IS  - 1432-1335 (Electronic)
IS  - 0171-5216 (Linking)
VI  - 144
IP  - 11
DP  - 2018 Nov
TI  - Middle East observational study in metastatic soft tissue sarcoma: an 
      epidemiological study on the treatment patterns (MOON).
PG  - 2219-2229
LID - 10.1007/s00432-018-2713-6 [doi]
AB  - PURPOSE: Soft tissue sarcomas (STS) are a heterogeneous group of rare mesenchymal 
      neoplasms, accounting for < 1% of all newly diagnosed malignancies. These tumors 
      can occur in almost any anatomic site though they most frequently occur in the 
      extremities. The objective of the study was to describe the epidemiology, 
      treatment paradigm, and real-world outcomes in the clinical management of 
      metastatic STS (mSTS) in the Middle East and North Africa (MEA) region. METHODS: 
      MOON was an observational, multicenter, retrospective patient chart review study 
      which included 200 patients with mSTS in the final analysis. The primary 
      objective of the study is exploratory, so it is presented using descriptive 
      statistics. RESULTS: At the time of presentation, 62.0% patients had metastatic 
      disease, 27.5% had received only their primary diagnosis and 10.0% had 
      experienced a local recurrence. The most frequent STS localizations were lower 
      extremities (74%), trunk (28.5%) and upper extremities (10.5%). Primary tumor was 
      staged as T2b in the majority (60%) of patients. Surgical treatment was performed 
      most often for the primary disease, whereas radiation therapy and chemotherapy 
      were predominantly administered with palliative intent. A total of 38 patients 
      received treatment with pazopanib. Thirteen adverse events (AEs) were attributed 
      to pazopanib in eight patients. CONCLUSION: Adult patients treated for STS have 
      al most equal gender ratio and mostly are middle aged. The majority of patients 
      have metastatic disease and disease progression, and half of the patients died 
      from the disease during the period of evaluation. This study obtained real-life 
      data on the clinical management of STS in MEA countries which could be shared 
      with the medical community.
FAU - Memon, Muhammad A
AU  - Memon MA
AD  - Medical Oncology, King Faisal Specialist Hospital and Research Center, Riyadh, 
      Saudi Arabia. memon@kfshrc.edu.sa.
FAU - Karaca, Burcak
AU  - Karaca B
AD  - Ege University, Izmir, Turkey.
FAU - Aboelhassan, Rasha
AU  - Aboelhassan R
AD  - Nasser Institute for Research and Treatment, Cairo, Egypt.
FAU - Barsoum, Mohsen
AU  - Barsoum M
AD  - National Cancer Institute Cairo University, Giza, Egypt.
FAU - Erman, Mustafa
AU  - Erman M
AD  - Hacettepe University, Ankara, Turkey.
FAU - Basaran, Mert
AU  - Basaran M
AD  - Istanbul University, Istanbul, Turkey.
FAU - Sevinc, Alper
AU  - Sevinc A
AD  - Department of Medical Oncology, Medical Park Gaziantep Hospital, Gaziantep, 
      Turkey.
FAU - Hanene, Djedi
AU  - Hanene D
AD  - Anticancer Center, Annaba, Algeria.
FAU - Slader, Cassandra
AU  - Slader C
AD  - Novartis Pharma AG, Basel, Switzerland.
FAU - Pilipovic, Virginia
AU  - Pilipovic V
AD  - Novartis Pharma AG, Basel, Switzerland.
FAU - Esma, Kerboua
AU  - Esma K
AD  - Centre Pierre et Marie Curie, Alger, Algeria.
FAU - Kamel, Bouzid
AU  - Kamel B
AD  - Centre Pierre et Marie Curie, Alger, Algeria.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
DEP - 20180813
PL  - Germany
TA  - J Cancer Res Clin Oncol
JT  - Journal of cancer research and clinical oncology
JID - 7902060
RN  - 0 (Indazoles)
RN  - 0 (Pyrimidines)
RN  - 0 (Sulfonamides)
RN  - 7RN5DR86CK (pazopanib)
SB  - IM
MH  - Adult
MH  - Africa, Northern/epidemiology
MH  - Aged
MH  - Aged, 80 and over
MH  - Drug Therapy/methods/statistics & numerical data
MH  - Female
MH  - Humans
MH  - Indazoles
MH  - Male
MH  - Middle Aged
MH  - Middle East/epidemiology
MH  - Neoplasm Metastasis
MH  - Pyrimidines/adverse effects/therapeutic use
MH  - Radiotherapy/methods/statistics & numerical data
MH  - Retrospective Studies
MH  - Sarcoma/*epidemiology/pathology/*therapy
MH  - Sulfonamides/adverse effects/therapeutic use
MH  - Surgical Procedures, Operative/methods/statistics & numerical data
OTO - NOTNLM
OT  - Epidemiological study
OT  - Middle East
OT  - Pazopanib
OT  - Real-world outcomes
OT  - Soft tissue sarcomas
EDAT- 2018/08/15 06:00
MHDA- 2018/11/07 06:00
CRDT- 2018/08/15 06:00
PHST- 2018/06/07 00:00 [received]
PHST- 2018/07/17 00:00 [accepted]
PHST- 2018/08/15 06:00 [pubmed]
PHST- 2018/11/07 06:00 [medline]
PHST- 2018/08/15 06:00 [entrez]
AID - 10.1007/s00432-018-2713-6 [pii]
AID - 10.1007/s00432-018-2713-6 [doi]
PST - ppublish
SO  - J Cancer Res Clin Oncol. 2018 Nov;144(11):2219-2229. doi: 
      10.1007/s00432-018-2713-6. Epub 2018 Aug 13.